Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing &amp;lt;italic&amp;gt;GLUT1&amp;lt;/italic&amp;gt; mRNA

Huang, Shan; Wu, Zheng; Cheng, Yi; Wei, Wen‐Cheng J.; Hao, Linlin

doi:10.1093/abbs/gmz048

Cited by 51 publications

(47 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this study, we focused on the PoRs (Figure 3A), since these represent factors that may promote dedifferentiation and diseases progression and may thus present therapeutic targets eligible for treatment by inhibition, as proposed for LIN28B [29] and other RBPs. Among the 44 PoRs were proteins previously implicated in PDAC progression, e.g., IGF2BP1-3 [13][14][15][16][17], IFIT3 [30], EXO1 [21], or PTBP3 [23]. However, there were also proteins that, to the best of our knowledge, have not yet been associated with oncogenic potential in pancreatic cancer, e.g., OAS proteins, RBM34 or DQX1.…”

Section: Transcriptional Regulation Of Rbps In Pdacmentioning

confidence: 96%

“…Despite the lack of systematic investigation of RBPs in PDAC, ample evidence suggests substantial impact of some RBPs in this malignancy. For example, all three members of the insulin-like growth factor 2 mRNA binding protein family (IGF2BPs) have recently been described as being upregulated and associated with a poor prognosis in pancreatic cancer [13][14][15][16][17]. Furthermore, inactivation of the histone deacetylase SIRT6 was reported to accelerate PDAC progression in mouse models due to upregulation of LIN28B [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma

Glaß

Michl

Hüttelmaier

2020

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinomas (PDAC) belong to the most frequent and most deadly malignancies in the western world. Mutations in KRAS and TP53 along with some other frequent polymorphisms occur almost universally and are likely to be responsible for tumor initiation. However, these mutations cannot explain the heterogeneity in therapeutic responses observed in PDAC patients, which limits efficiency of current therapeutic strategies. Instead, recent classifications of PDAC tumor samples are based on transcriptomics data and thus include information about epigenetic, transcriptomic, and post-transcriptomic deregulations. RNA binding proteins (RBPs) are important post-transcriptional regulators involved in every aspect of the RNA life cycle and thus considerably influence the transcriptome. In this study, we systematically investigated deregulated expression, prognostic value, and essentiality reported for RBPs in PDAC or PDAC cancer models using publicly available data. We identified 44 RBPs with suggested oncogenic potential. These include various proteins, e.g., IGF2 mRNA binding proteins (IGF2BPs), with reported tumor-promoting roles. We further characterized these RBPs and found common patterns regarding their expression, interaction, and regulation by microRNAs. These analyses suggest four prime candidate oncogenic RBPs with partially validated target potential: APOBEC1, IGF2BP1 and 3, and OASL.

show abstract

Section: Transcriptional Regulation Of Rbps In Pdacmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma

Glaß

Michl

Hüttelmaier

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In recent years, over-expression of IGF2BP2 in multiple human cancers has been associated with poorer prognosis of the disease. For instance, over-expression of IGF2BP2 confers shorter survival and poor prognosis of patients with acute myelocytic leukemia (AML) [65], breast cancer [14], esophageal carcinoma [16], low-grade gliomas [17], hepatocellular carcinoma (HCC) [66], head and neck squamous cell carcinoma (HNSCC) [67], pancreatic ductal adenocarcinoma (PDAC) [20,[68][69][70] and gallbladder carcinoma (GBC) [71]. Herein, we summarize the specific roles of IGF2BP2 in multiple cancers and provide a comprehensive view of IGF2BP2 ( Fig.…”

Section: Igf2bp2 and Cancersmentioning

confidence: 99%

“…IGF2BP2 is also over-expressed in PDAC [68,69]. Meanwhile, Glucose transporter 1 (GLUT1) is an integral membrane protein consisting of 12 transmembrane helices and an intracellular domain which promotes aerobic glycolysis and proliferation of cancer cells [75][76][77].…”

Section: Igf2bp2 In Pancreatic Cancermentioning

confidence: 99%

The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers

2021

View full text Add to dashboard Cite

The human insulin-like growth factor 2 (IGF2) mRNA binding proteins 2 (IGF2BP2/IMP2) is an RNA-binding protein that regulates multiple biological processes. Previously, IGF2BP2 was thought to be a type 2 diabetes (T2D)-associated gene. Indeed IGF2BP2 modulates cellular metabolism in human metabolic diseases such as diabetes, obesity and fatty liver through post-transcriptional regulation of numerous genes in multiple cell types. Emerging evidence shows that IGF2BP2 is an N6-methyladenosine (m6A) reader that participates in the development and progression of cancers by communicating with different RNAs such as microRNAs (miRNAs), messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs). Additionally, IGF2BP2 is an independent prognostic factor for multiple cancer types. In this review, we summarize the current knowledge on IGF2BP2 with regard to diverse human metabolic diseases and its potential for cancer prognosis.

show abstract

“…CNP was correlated with survival and could be used as a novel and potentially useful clinical prognosis biomarker in glioblastoma multiforme [39]. The expression of IGF2BP2 was up-regulated and led to a poor prognosis in pancreatic ductal adenocarcinoma [40] and acute myelocytic leukemia [41]. PABPC1L was emerging as a promising prognostic factor for colon cancer [42].…”

Section: Discussionmentioning

confidence: 99%

Integrated analysis of the functions of RNA binding proteins in clear cell renal cell carcinoma

Hua¹,

Chen

Ge³

et al. 2021

Genomics

View full text Add to dashboard Cite

Background: RNA binding proteins (RBPs) dysregulation is involved in the process es of various tumor. However, the roles of RBPs in clear cell renal cell carcinoma (ccRCC) remain poorly understand. Systematic exploration of the roles of RBPs in ccRCC may provide new insights for the treatments of ccRCC. Methods: Expression data of RBPs was obtained from The Cancer Genome Atlas database. The roles of RBPs in ccRCC were systematically investigated using consensus clustering methods. Differentially expressed RBPs between normal and tumor tissues were obtained. Protein-protein interaction (PPI) network was constructed using "STRING" software. The expression levels of hub genes were validated in The Human Protein Atlas (HPA) database and receiver operating characteristic (ROC) curves were used to evaluate diagnostic value. Univariate and Lasso Cox regression and Kaplan-Meier curves were used to screen the most useful prognostic genes. Multivariate Cox regression was performed to construct a risk score model. The e ciency of the model was evaluated using time-dependent ROC and Kaplan-Meier curves, and validated in E-MTAB-3267 set. Results: Two clusters were identi ed based on the expression similarity of RBPs, and the cluster 2 was closely correlated with the malignancy of ccRCC. Several oncogenic pathways, including epithelial mesenchymal transition, G2M checkpoint, KRAS signaling and IL6 JAK STAT3 signaling were enriched in cluster 2. In addition, we obtained 115 differently expressed RBPs in ccRCC, comprising 71 up-regulated and 44 down-regulated ones. Ten hub RBPs with good diagnostic value were obtained from PPI network and validated in HPA database. Ten RBPs were identi ed as survival-related genes and used to construct a risk score model. The model could be used to stratify patients with different prognosis. We found highrisk patients tended to be advanced stage, high grade, high pathological T staging and could be an independent risk factor for overall survival of ccRCC patients. Conclusions: We identi ed ten RBPs with diagnostic value, which might be the potential diagnostic biomarkers for ccRCC. A risk score model was established to stratify patients and could be used as a complementation for clinical factors to guide clinical practice in the future.

show abstract

Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing <italic>GLUT1</italic> mRNA

Cited by 51 publications

References 33 publications

RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma

RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma

The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers

Integrated analysis of the functions of RNA binding proteins in clear cell renal cell carcinoma

Contact Info

Product

Resources

About